This India-focussed pharma player, with healthy prospects, is asking for a high price

The initial public offer of Ahmedabad-based specialty pharma company Eris Lifesciences (Eris) is underway. The issue is an offer-for-sale by promoters and other shareholders in the price band of ₹600-603.The company has charted a strong growth path so far on the back of its focus on lifestyle-related specialised therapeutic areas in the Indian market, a high growth opportunity. A low base has also...